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Abstract 23 
Systemic lupus erythematosus (SLE) is an autoimmune disease, characterised by increased 24 
expression of type I interferon (IFN) regulated genes and a striking sex imbalance towards 25 
females. Through combined genetic, in silico, in vitro, and ex vivo approaches, we define 26 
CXorf21, a gene of hitherto unknown function, which escapes X-chromosome inactivation, as 27 
a candidate underlying the Xp21.2 SLE association. We demonstrate that CXorf21 is an IFN-28 
response gene and that the sexual dimorphism in expression is magnified by immunological 29 
challenge. Fine-mapping reveals a single haplotype as a potential causal cis-eQTL for CXorf21. 30 
We propose that expression is amplified through modification of promoter and 3-UTR 31 
chromatin interactions. Finally, we show that the CXORF21 protein colocalises with TLR7, a 32 
pathway implicated in SLE pathogenesis. Our study reveals modulation in gene expression 33 
affected by the combination of two hallmarks of SLE: CXorf21 expression increases in a both 34 
an IFN-inducible and sex-specific manner.  35 
  36 
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Introduction 37 
Females have a clear immunological advantage over males, with reduced susceptibility to 38 
infection at an early age and a superior ability to produce antibodies and serum IgM following 39 
immune challenge1,2. The immunological gain in females is thought to contribute to the striking 40 
sexual dimorphism observed in human autoimmune disease - where over 80% of sufferers are 41 
female3 - and corroborates the hypothesis that genetic risk to autoimmunity is an evolutionary 42 
consequence of positive selection for favourable immune responses to infection4. Systemic 43 
lupus erythematosus (SLE), an autoimmune disease characterised by anti-nuclear 44 
autoantibodies and a type I interferon (IFN) signature, displays one of the most striking female-45 
biased imbalances (9:1) in disease prevalence. Although the underlying mechanism has yet to 46 
be fully elucidated, a prominent role of X chromosome dosage is supported by the karyotypic 47 
risks for SLE. Males with Klinefelter’s syndrome (47, XXY) have a 14-fold increased 48 
prevalence of SLE compared to 46, XY males, which approximates to the prevalence seen in 49 
46, XX females5. Furthermore, whereas 45, XO females have lower risk6, SLE prevalence in 50 
47, XXX females is ~2.5 times higher than in 46, XX females7. Indeed, mammalian X 51 
chromosomes, for which males are hemizygous, are enriched for immune-related genes8.  52 
 53 
X chromosome inactivation (XCI) is a unique mammalian dosage-compensation mechanism 54 
which equalises expression of X-linked genes between sexes9. This random process results in 55 
either the paternally or maternally inherited X chromosome becoming inactivated (Xi) through 56 
enriched heterochromatic modifications, which promotes gene silencing to leave one 57 
transcriptionally active X chromosome (Xa) in females10. However, an estimated 15% of X-58 
linked genes, preferentially found on the Xp arm, escape XCI and thus display expression from 59 
both chromosomes, although typically expression is still lower from the Xi compared with 60 
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Xa11. A further 10% of X-linked genes display variable expression from the Xi – an observation 61 
which itself is variable between both individuals and cell types, and throughout development 62 
and ageing12. It is these XCI-escaping genes, through their partial or complete lack of dosage 63 
compensation, that are thought to contribute to genetic sexual dimorphism and phenotypic 64 
differences in X-chromosome aneuploidies13. Furthermore, the relaxation of Xi silencing in 65 
female mammals includes increases in the expression of several immunity-related genes14. 66 
How genes that escape XCI contribute to sexually dimorphic diseases has not been thoroughly 67 
studied.  68 
A SLE association at the Xp21.2 locus (rs887369; PMETA = 5.26 x 10
-10; OR = 1.15) was 69 
recently identified in a European GWAS and replication study15. Intriguingly, this locus is 70 
encoded outside the pseudo autosomal region (PAR) and the lead SNP (a synonymous variant) 71 
resides in the final exon of CXorf21, a protein-coding gene of unknown function. CXorf21 has 72 
been shown to escape XCI in lymphoblastoid cell lines (LCLs), and is one of only 14 X-linked 73 
genes that is differentially expressed between Klinefelter’s syndrome (47, XXY) and 46, XY 74 
males in LCLs16,17. A recent whole-blood gene expression study also identified CXorf21 as one 75 
of seven genes upregulated in female SLE patients displaying disease flare relative to those 76 
with infection18.  77 
  78 
Despite the stark karyotypic risk, there remains a lack of understanding of the contribution of 79 
the X chromosome to SLE, which is a leading cause of death in females aged under 34 years of 80 
age19. Here we describe fine-mapping and characterisation of the association at Xp21.2 through 81 
complementary genetic, in silico, in vitro and ex vivo approaches using both existing and newly 82 
generated data (all methods are summarised as a flow chart in Supplementary Fig. 1). We 83 
demonstrate that the candidate gene, CXorf21, is an IFN-responder with both cell-type specific 84 
and sexually dimorphic expression amplified by cellular activation. Additionally, we provide 85 
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evidence at the protein-level of CXORF21 co-localisation with TLR7; a gene causatively 86 
linked to SLE and which also evades XCI. Our study demonstrates IFN-inducible 87 
magnification of sexual dimorphic gene expression contributing to SLE risk.  88 
  89 
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Results 90 
Genetic refinement of the Xp21.2 SLE susceptibly locus 91 
The source of all cohorts used within this manuscript along with the analyses performed are 92 
presented as a flow diagram in Supplementary Fig. 1. The UK10K-1000 Genomes Project 93 
Phase 3 reference panel20 was firstly used to impute the Xp21.2 locus of the Bentham and 94 
Morris et al SLE GWAS (10,995 individuals of European ancestry)15. Logistic regression 95 
revealed a synonymous variant, rs887369 (MAF = 0.24), to be the most significantly associated 96 
SNP (P = 3.34 x 10-7; OR = 1.43, 95% C.I = 1.23-1.66; Fig. 1a) and conditional analysis upon 97 
rs887369 showed no evidence of independent association signals (Fig. 1b). Haplotype analyses 98 
revealed that rs887369 tags a single, 1kb haplotype block comprising five near-perfectly 99 
correlated SNPs mapping to the 3 region of CXorf21 (Fig. 1c)– encoding a small, 301-amino 100 
acid protein of unknown function. SNPs rs2529517 (distal) and rs887369 (proximal) define the 101 
boundaries of the associated haplotype, which map downstream of the 3-UTR of CXorf21, and 102 
to the gene’s third and final exon respectively (Fig. 1c). Three of the five associated SNPs are 103 
transcribed from CXorf21, with rs887369 effecting a synonymous change (V209) and both 104 
rs2532873 and rs2710402 residing in the 3-UTR. The remaining two SNPs, rs2429517 and 105 
rs2429518, are located in the downstream intergenic region of CXorf21. The associated 106 
haplotype is distinctly separated from neighbouring haplotypes by high recombination (D < 107 
0.6, r2 < 0.2) and accordingly, the risk haplotype itself represents the only observed association 108 
with SLE (2 = 29.87, P = 4.63 x 10-8; Chi-Square test; Fig. 1d).  109 
 110 
CXorf21 is known to escape XCI16. We performed a statistical test on the association with 111 
rs887369 to see if a model that assumed the SNP was in an area that escaped inactivation fitted 112 
better than a model assuming full inactivation. A likelihood ratio test to fit both association 113 
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models failed to reject the model of full inactivation (P = 0.78). Therefore, from our 114 
case/control data we have no evidence against the hypothesis that this association lies in an 115 
area of full inactivation. To extend these analyses, we determined the odds ratios of the risk 116 
alleles in females and males separately. We observed a higher odds ratio for females 117 
homozygous for the rs887369 [C] risk allele with respect to homozygous for [A] non-risk (OR 118 
= 1.58, 95% C.I. 1.29 – 1.93) compared to the males (OR = 1.46, 95% C.I. = 1.10 – 1.92), who 119 
are hemizygous for the risk or non-risk alleles. The higher odds ratio in females is likely to 120 
reflect a gene dosage effect secondary to some degree of loss of X inactivation.  121 
 122 
The risk haplotype increases expression of CXorf21 in LCLs 123 
As no protein-altering variants were identified through fine-mapping, we sought to establish 124 
whether the SLE risk alleles at CXorf21 colocalised with cis-eQTLs for gene transcription. 125 
Non-random inactivation of the X chromosome (skewing) and variability in the degree of 126 
silencing of gene expression from the inactivated X in females complicates the identification 127 
of X chromosome eQTLs in females. Therefore, to study cis-eQTLs at the CXorf21 locus, we 128 
employed two complementary methods of assessing the influence of the risk haplotype, tagged 129 
by rs887369, on the expression of genes within the Xp21.2 region: 1) using the hemizygosity 130 
of males to isolate the allelic effects; 2) removing females exhibiting strong evidence of 131 
extreme skewed XCI to reduce the variability in the degree of skewing of X-chromosome 132 
expression.  133 
 134 
The associated haplotype, tagged by rs887369 [C], correlated with increased expression of 135 
CXorf21 in LCLs from male samples in the Geuvadis RNA-Seq dataset ( = 1.56, P = 1.94 x 136 
10-03; linear-regression; Fig. 2a). The expression of neighbouring genes GK and TAB3 showed 137 
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no significant association with rs887369 (P = 0.7 and P = 0.09, respectively, linear-regression, 138 
Fig. 2a). Many variants may act as cis-eQTLs, however it is important to note that rs887369 139 
was the most significantly associated cis-eQTL for CXorf21 (Fig. 2b) and the remaining cis-140 
genes (the MAGEB family and NR0B1; +/-1Mb from rs887369) were not expressed in LCLs 141 
(RPKM < 1).  142 
The allelic effect on CXorf21 expression was only nominally significant when performing the 143 
cis-eQTL analyses in female individuals from Geuvadis RNA-Seq dataset in LCLs (P = 0.02; 144 
linear-regression; Supplementary Fig. 2a). In order to investigate cis-eQTL effects at rs887369 145 
in females, we interrogated an additional RNA-Seq gene expression dataset in LCLs 146 
constructed exclusively from female donors from the TwinsUK cohort21. This dataset was 147 
selected for analysis as it had been previously analysed for skewing of X chromosome 148 
inactivation using allele specific expression (ASE) of the Xist silencing lncRNA (manuscript 149 
in preparation). In order to study potential cis-eQTLs at the CXorf21 locus, we removed 150 
individuals showing marked skewing, in whom the Xist ASE showed that one parental X 151 
chromosome contributed less than 20% of the Xist expression. In this subset of 412 non-skewed 152 
individuals, we observed a statistically significant increase of CXorf21 expression with respect 153 
to the rs887369 [C] risk allele in females (P = 7.00 x 10-03; linear-regression; Fig. 2c).  154 
 155 
We validated this effect in vitro by qPCR of independent LCL samples selected from the 156 
HapMap Project on the basis of their genotype at rs887369. In these cells a 1.9-fold increase 157 
of CXorf21 mRNA was detected between rs887369 homozygous risk and non-risk females (P 158 
= 4.1 x 10-5; t-test ;Supplementary Fig. 2b). Following validation of the anti-CXORF21 159 
antibody (Supplementary Fig. 3), the observed increase in expression by the risk allele was 160 
found to persist at protein-level ( = 0.49, P = 2.88 x 10-5; Fig. 2d; raw data are shown in 161 
Supplementary Fig. 2c).  162 
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 163 
Risk variants increase CXorf21 expression upon activation 164 
We expanded our analysis and interrogated a genotype-expression cohort from a range of 165 
human primary ex vivo immune cells. When assessing male samples only, we found that the 166 
associated haplotype, tagged by rs887369, was a significant cis-eQTL for CXorf21 in both 167 
Lipopolysaccharide (LPS) stimulated (P = 1.08 x 10-03) and IFN-γ-stimulated (P = 1.10 x 10-168 
3; linear-regression) monocytes (Fig. 2e). The [C] risk allele once again correlated with 169 
increased CXorf21 expression. Interestingly, no statistically significant cis-eQTL associations 170 
were observed in the unstimulated experiments: B cells, NK cells, neutrophils, and monocytes, 171 
which suggests an activation-state specificity of the cis-eQTL. When the same analysis was 172 
performed in the female samples of the same cohort, no significant cis-eQTLs were detected 173 
in any of the cell types (Supplementary Fig. 2d).  174 
 175 
Epigenetic fine-mapping of the Xp21.2 associated haplotype  176 
Using the Roadmap Epigenomes Project22 (twelve different histone marks across 127 cell and 177 
tissue types), we used chromatin fine-mapping to functionally prioritize the five SNPs carried 178 
on the 1Kb associated haplotype. The associated SNPs localised only to a single histone 179 
modification, H3K36me3, across five cell types: blood mononuclear cells, peripheral blood B 180 
cells, monocytes, neutrophils, and the lymphoblastoid cell line GM12878. Analysis of the 181 
signal value distribution of H3K36me3, designating regions of active transcription, across 182 
these cell types revealed that rs887369 localised to the binding site summit of H3K36me3 183 
whilst the remaining four SNPs on the haplotype localised to the tails of the signal distribution 184 
(Fig. 3a). The greatest enrichment of H3K36me3 across the entire CXorf21 gene locus was 185 
concentrated to +/-100bp of rs887369 in monocytes (P = 6.1 x 10-14; MACS2) and neutrophils 186 
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(P = 2.0 x 10-17; MACS2; Fig. 3b). The rs887369 SNP also localised to the binding site summit 187 
of H3K36me3 in primary B cells, LCLs, and blood mononuclear cells, with significant, albeit 188 
weaker enrichment.  189 
 190 
As verification, we performed the same analysis using ChIP-Seq experiments (n=612) from 191 
the venous blood portion of the Blueprint Epigenetics consortium23 (8 modifications across 24 192 
unique cell types from 83 donors). Only 22 ChIP-Seq experiments presented evidence of 193 
overlap with the SLE-associated haplotype, and strikingly, all of these intersections were again 194 
for the H3K36me3 chromatin modification. No other histone modifications intersected this 195 
region. All five SNPs on the 1kb SLE-associated haplotype were found to overlap with 196 
H3K36me3 in monocytes, B cells and neutrophils – corroborating the Roadmap Epigenomics 197 
data. We were unable to make robust conclusions on differential H3K36me3 signal between 198 
the sexes as the sample sizes per cell-type were too small (Supplementary Fig. 4, 199 
Supplementary Table 1).  200 
 201 
Lastly, the associated SNPs in the 3-UTR of CXorf21 showed no evidence of disrupting a 202 
microRNA binding site after interrogation using miRDB24.  203 
 204 
The risk haplotype interacts with the promoter of CXorf21  205 
We sought to investigate a conceivable molecular mechanism whereby the SLE-associated 206 
haplotype at the 3 end of CXorf21 modulates expression through alteration of chromosome 207 
interactions. The promoter capture Hi-C dataset curated by the CHiCP resource25 was 208 
interrogated. This resource comprises Hi-C data from 17 primary immune cell types taken from 209 
healthy donors. Three of the five SNPs (rs887369, rs2710402, and rs2532873) on the 210 
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associated haplotype, which are closest to CXorf21, reside within the chrX:30576528-211 
30582605 target region. Across all primary immune cell types tested, the target region was 212 
found to interact with four baits (Fig. 3c): the promoter region of CXorf21 (chrX:30595248-213 
30603761); the promoter of GK; and two intronic antisense RNAs of TAB3 (TAB3-AS1 and 214 
TAB3-AS2). Significant bait-target region interactions (CHiCAGO score ≥ 5) were detected 215 
exclusively in neutrophils (Fig. 3d), where the CXorf21 promoter bait interaction presented the 216 
greatest strength of interaction with the risk haplotype target region (6.09). Strong but sub-217 
threshold interactions (3 ≤ CHiCAGO score < 5) were also detected for the risk haplotype 218 
target and the CXorf21 promoter bait region in monocytes (3.72) and naïve B cells (3.15). The 219 
strength of the interaction score between the risk haplotype target region and the CXorf21 220 
promoter was found to correlate strongly with the signal strength of epigenetic marks (from 221 
ENCODE26) indicative of active gene-expression (H3K4me3 and H3K27ac) for matched cell 222 
types (Fig. 3e). These findings suggest that the 3-promoter interaction of CXorf21 is more 223 
pronounced in the cell types in which CXorf21 is expressed, and the interaction itself is 224 
involved in regulation of expression. In fact, by assessing the transcription factor landscape at 225 
the CXorf21 locus, we found significant binding events of RNA polymerase II (POLR2A) at 226 
the 3 SLE-associated region in immune cell types only; corroborating our hypothesis that the 227 
observed chromatin looping is necessary for transcriptional regulation (Supplementary Fig. 5).  228 
 229 
Sexual dimorphic expression is magnified upon activation 230 
GTEx RNA-Seq data27 across 45 different cell/tissue types confirmed that there is significant 231 
sexual dimorphic expression of CXorf21 in both LCLs and thyroid tissue (LCLs: 1.78-fold 232 
greater in females, P = 1.10 x 10-5, thyroid: 1.33-fold greater, P = 2.65 x 10-3 following 233 
Bonferroni multiple testing correction; t-test; Supplementary Fig. 6a and Supplementary Table 234 
12 
 
2). Neighbouring genes GK and TAB3 were equally expressed in both sexes, in both LCLs and 235 
in the cell types in which both genes are most expressed, suggesting escape from XCI at this 236 
locus is restricted to CXorf21. Using HapMap LCLs selected on the basis of their genotype at 237 
haplotype-tagging rs887369, we employed the validated anti-CXORF21 antibody 238 
(Supplementary Fig. 3) to quantify protein abundance by western blot. When we examined cell 239 
lines that all carried at least one risk haplotype, we confirmed that protein expression was 240 
higher in females (Supplementary Fig. 6b): females harboured 3.6 times more CXORF21 than 241 
males (P = 0.006; t-test). These findings imply that the slight variation in CXorf21 mRNA 242 
results in an amplified effect on overall protein abundance. To ensure these results were not a 243 
consequence of monoallelic expression of CXorf21 in pauciclonal LCLs, we assayed CXorf21 244 
expression from microarray experiments across a range of primary ex vivo immune cells and 245 
found, as with other XCI escaping genes, the effect size of CXorf21 expression between sexes 246 
was cell-type specific11. In resting B cells, NK cells, neutrophils, and monocytes, no significant 247 
difference in transcript abundance of CXorf21 between sexes was observed (Supplementary 248 
Fig. 6c, Supplementary Table 3). However, though we see global increase of CXorf21 249 
expression in both sexes, a striking sexual dimorphic responses to LPS- or IFN-γ-stimulation 250 
in monocytes was observed (Fig. 4; PLPS = 1.41x10
-12;  PIFN-γ = 9.29 x10
-8; t-test). Transcript 251 
abundance of CXorf21 in monocytes is therefore greatest in females under immune-stimulated 252 
conditions.  253 
 254 
CXorf21 is a likely interferon response gene 255 
Given the marked increase of CXorf21 expression in stimulated immune cells (including LCLs 256 
which exhibit a partially activated phenotype28) and the observed up-regulation of IFN-257 
regulated genes in SLE29, we investigated whether CXorf21 is an interferon response gene by 258 
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profiling gene expression using in-house microarray data in primary ex vivo B cells taken from 259 
healthy females (n=49 in total, of which n=32 were treated with IFN-). We observed CXorf21 260 
is one of eighteen X chromosome genes (including TLR7, IL13RA1, and ELF4) which were 261 
up-regulated in response to IFN- stimulation (fold-change: 2.41; P = 6.0 x 10-9; ANOVA; 262 
Fig. 5a). No other Xp21.1 gene was modulated by IFN-. We profiled the epigenetic landscape 263 
surrounding the CXorf21 locus in ENCODE data and detected significant and localised binding 264 
events of NF-B, STAT1, STAT2, STAT3, IRF4, and IRF3 at the immediate promoter region 265 
of CXorf21 in LCLs (Fig. 5b). We also identified a single interferon-stimulated response 266 
element (ISRE) +25bp upstream of the CXorf21 transcription start site (TSS). This sequence 267 
motif and the array of interferon regulatory factors was not detected in any of the promoters of 268 
other genes within the Xp21.2 locus (Fig. 5b).   269 
 270 
Functional characterisation of the Xp21.2 SLE rick locus 271 
Eight genes are encoded at the Xp21.2 SLE risk locus (rs887369; P = 3.34 x 10-7; OR = 1.43): 272 
four Melanoma Antigen B (MAGEB) family genes (MAGEB1-4), NR0B1 encoding the DAX1 273 
nuclear receptor, GK (glycerol kinase), TAB3 (TGF-beta activated kinase 1 and MAP3K7 274 
binding protein 3), and CXorf21 (Fig. 1a; Supplementary Table 4). None of these eight genes 275 
had reported associations with immune-related phenotypes in human or mouse.  276 
 277 
CXorf21 is the only gene in the locus with a discrete immune-specific mRNA expression 278 
profile; being most highly expressed in the spleen, appendix, bone marrow, and lymph nodes 279 
(Protein Atlas; Supplementary Fig. 7, GTEx and FANTOM5 validation in Supplementary Fig. 280 
8). This suggests the mechanism by which the SLE-risk haplotype is affecting disease risk is 281 
through candidate gene CXorf21. To refine this analysis in terms of cellular expression, we 282 
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used data from Blueprint Epigenome (RNA-sequencing) and BioGPS (microarray) to show 283 
that within immune cell types, the expression of CXorf21 is largely restricted to monocytes, 284 
neutrophils, and B cells (Supplementary Fig. 9). We corroborated these findings in RoadMap 285 
Epigenomics data and found a striking chromatin landscape around the transcription start site 286 
of CXorf21, indicative of epigenetic silencing in non-immune cell types (Supplementary Fig. 287 
10). The expression profile of CXorf21 at protein-level was largely consistent with the mRNA 288 
data; though CXORF21 protein was found to be in equal abundance in certain secondary 289 
immune tissue such as the bowel and skin (Supplementary Fig. 11). 290 
 291 
RNA-Seq co-expression analysis across a range of human cell and tissue-types was undertaken 292 
using the COEXPRES algorithm30. The results indicate that GPR65 (G-couple protein receptor 293 
65) tops the ranking, whose protein product is important in lysosomal function31. Examination 294 
of the top 100 ranked genes revealed the expression signature of CXorf21 correlated with the 295 
Toll-like receptor (TLR) signalling pathway including TLR7, TLR6, PIK3CG, and PIK3CD 296 
(Supplementary Table 530), of which TLR7 was highest ranked. The correlation between the 297 
expression of the two X-linked genes, CXorf21 and TLR7, was replicated in TwinsUK RNA-298 
Seq data21 from LCLs from non-skewed females (n= 271;  = 0.38; P = 6 x 10-11).  299 
 300 
In order to gain further insight into the potential function of CXORF21, we utilized high-301 
throughput affinity-purification mass spectrometry data from BioPlex32 and revealed a high 302 
confidence (quantitative score: 0.999) protein-protein interaction between CXORF21 and 303 
SLC15A4, encoded by the SLE susceptibility gene SLC15A4 (rs1059312; PMETA=1.48x10
−13; 304 
OR=1.17)15. SLC15A4 is an immune-restricted lysosomal amino-acid transporter required for 305 
TLR7- and TLR9-mediated type I IFN production in dendritic cells and B cells in lupus33.  306 
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Interestingly, in the BioPlex data, CXORF21 was also found to interact with itself, suggesting 307 
probable oligomerization of this protein.  308 
 309 
Protein level correlates with disease activity in females 310 
In a modest cohort (ncases = 19; ncontrols = 13) we did not observe a statistically significant 311 
difference in CXORF21 protein abundance between female case and controls in CD14+ 312 
monocytes or CD19+ B cells (Supplementary Fig. 12). However, we observed an age-313 
dependent correlation between CXORF21 and SLE Disease Activity Index 314 
(SLEDAI). CXORF21 protein abundance is positively correlated with SLEDAI in SLE 315 
females < 35 years of age (CXORF21 ~ SLEDAI * Stratified Age) in both CD14+ monocytes 316 
and CD19+ B cells (Supplementary Fig. 13). A likelihood ratio test (LRT) rejected the model 317 
of SLEDAI as a single variable (upper panels Supplementary Fig. 13) in favour of an 318 
interaction model in monocytes (LRT P = 0.0002) and B cells (LRT P = 0.0006). The rejection 319 
of the single variable models are also supported by BIC (BICmonocytes  = 8.1; BICBcells  = 320 
5.9). We observed a significant interaction term (SLEDAI * Stratified Age) in monocytes (P = 321 
0.002), though the interaction term in B cells did not pass multiple testing correction (P = 322 
0.011; lower panels Supplementary Fig. 13). 323 
 324 
CXORF21 protein may act within endosomal pathway  325 
CXORF21 is a small protein of ~34kDa as identified by Western Blot. Very little of the 326 
secondary/tertiary protein structure of CXORF21 could be accurately determined by the Phyre 327 
bioinformatics prediction tool34.  Thus, to gain insight into the protein’s function we sought to 328 
determine its cellular location in ex vivo cells from healthy females and the GM12878 329 
lymphoblastoid cell line. We undertook multispectral imaging flow cytometry (MIFC) with a 330 
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range of labels for different organelles. The results demonstrated minimal co-localisation of 331 
CXORF21 with nuclear, Golgi or lysosomal markers in ex vivo PBMCs, and this was not 332 
affected by IFN stimulation (Supplementary Fig. 14 and 15).  In view of these negative findings 333 
and the data showing co-expression of CXorf21 with components of the Toll-like receptor 334 
signalling pathway (Supplementary Table 6), we utilised the increased resolution of structured 335 
illumination microscopy (SIM) to determine whether there was any evidence for colocalisation 336 
of CXORF21 with TLR7. Representative images for the staining in resting and stimulated ex 337 
vivo B cells are shown (Fig. 6a through 6d). We quantified the correlation between signals 338 
obtained from CXORF21 with TLR7 staining (Fig. 6e) and determined the colocalisation of 339 
the two staining signals in B cells using Mander’s co-efficient (see Methods). These analyses 340 
were undertaken in both resting B cells and stimulated B cells (B cell receptor cross-linking 341 
and CD40) and in each case with and without exposure to IFN-. We conclude that there is 342 
weak colocalisation between TLR7 and CXORF21 in ex vivo B cells (Pearson correlation 0.3 343 
<  < 0.4).  No significant differences in colocalisation between CXORF21 and TLR7 were 344 
observed after IFN-α treatment of resting or IgM/CD40 stimulated B cells.  345 
 346 
As the endosomal intracellular pathway interacts with the autophagy pathway (which has also 347 
been implicated in SLE pathogenesis)35 we sought to determine whether CXORF21 colocalised 348 
with autophagosomes, once more utilising SIM. Using LC3 as a marker of the autophagosome, 349 
representative results of the joint staining (LC3 and CXORF21) are shown for Ig/CD40 350 
stimulated B cells (Fig. 7a) with exposure to the inhibitor of autophagic flux, bafilomycin (Fig. 351 
7b), and Ig/TLR7/8 stimulated B cells (Fig. 7c) with bafilomycin (Fig. 7d). The results from 352 
multiple cells are summarised in Fig. 7e and 7f, which show no colocalisation between LC3 353 
and CXORF21 in bafilomycin-treated ex vivo B cells when stimulated with Ig/CD40 or 354 
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Ig/TLR7/8. Assaying CXORF21 protein abundance by western blot in starved LCL (see 355 
methods) indicates that the amount of CXORF21 is not altered by the addition of bafilomycin 356 
and hence it is unlikely that CXORF21 is an autophagy substrate (Fig. 7g; left panel). The blot 357 
shows some elevation of sequestome 1 (p62), an autophagosome cargo protein, following 358 
exposure to bafilomycin, which would be expected (Fig. 7g; right panel). 359 
  360 
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Discussion 361 
The underrepresentation of genetic associations on the X chromosome in autoimmune disease 362 
is highly paradoxical given the prominent sex bias towards females and the increased density 363 
of immune related genes compared to the autosomes. This is partly due to the paucity of sex 364 
chromosome data in genome-wide studies; only 33% of GWAS report sex chromosome data36. 365 
We sought to functionally investigate the undefined SLE susceptibility locus Xp21.2 from our 366 
own GWAS dataset (rs887369; P = 3.34 x 10-7; OR = 1.43). Our investigation defines CXorf21 367 
– encoding a protein of hitherto unknown function – as the candidate gene and demonstrates 368 
its expression is upregulated through by a number of distinct factors: chromosome X dosage 369 
and loss of XCI, the risk haplotype (tagged by rs887369), and cellular activation by interferon 370 
(summarised in Fig. 8). Our study supports the hypothesis that altered expression of X-linked 371 
genes contributes to the sexual dimorphism in autoimmunity14 and provides some preliminary 372 
evidence for the role of CXorf21 in SLE, although this topic clearly warrants further 373 
investigation. 374 
 375 
To date, six X-encoded SLE susceptibility loci have been identified, and four have been shown 376 
to harbour genes that escape XCI (TLR7, TMEM187, IRAK1, and CXorf21). Of these, CXorf21 377 
is the most robustly escaping; possessing evidence of escape in ~80% of individuals in contrast 378 
to the remaining genes that exhibit escape in <30%16. We show that escape from XCI is highly 379 
localised to CXorf21 across a +/-1Mb window.  380 
 381 
The Xp21.2 locus is not as strongly associated with SLE in individuals of non-European 382 
ancestry, although an association has been reported in Koreans37. This is partially explained by 383 
the marked disparity in allele frequency of risk allele rs887369 [major allele: C] between 384 
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populations (1000Genomes: 0.76 in Europeans, 0.92 in Africans, 0.95 in Asians). The lower 385 
minor allele frequency in non-Europeans may clearly impact on power, especially as non-386 
European GWAS have been of smaller sample size. The fraction of individuals who exhibit 387 
XCI of CXorf21 is reported to be diminished in individuals of African descent (relative to those 388 
of European descent16); however, lower allele frequencies of transcribed polymorphisms and 389 
limited samples sizes impede power. Whether allele frequency of rs887369 and reduced XCI 390 
escape are correlated or whether variation at rs887369 itself is causal to a degree of escape 391 
poses an interesting line of enquiry. Furthermore, the reduced level of escape in non-Europeans 392 
may mean the effect size will limit the power of this locus to be detected. 393 
 394 
CXorf21 has a discrete expression pattern in immune cells, both adaptive and innate, with the 395 
greatest expression of CXorf21 found in monocytes and neutrophils, primary B cells and LCLs. 396 
It appears to be epigenetically inert in non-immune cell types, suggesting the regulatory 397 
mechanisms driving expression of CXorf21 are not present in non-immune cell types. These 398 
data align with the observation that other candidate genes of SLE and their accompanying 399 
causal variants exhibit a discrete expression signature and cis-regulatory landscape that is 400 
largely restricted to immune cell subsets; particularly B cells (including B-lymphoblastoid cell 401 
lines), T cells, and monocytes15,38–40.  402 
 403 
We demonstrate that CXorf21 expression is upregulated in LPS and IFN-γ-stimulated 404 
monocytes, and in IFN-α-stimulated B cells, with the magnitude of increase greater in females 405 
leading to significant sexually dimorphic expression levels. We have also identified binding 406 
sites of respective transcription factors from these signalling cascades: IRF3, NF-κB and 407 
STAT1-3 at the immediate promoter of CXorf21suggesting CXorf21 transcription could be a 408 
primary response gene of the TLR4 (IRF3) and IFN (STATs) signalling pathways. However, 409 
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CXorf21 expression decreases following acute (2h) LPS-stimulation, suggesting CXorf21 is in 410 
fact a late response gene induced by secondary activation of the TLR4-induced type I IFN feed 411 
forward loop41. Indeed, late response genes are characterised by STAT binding sites and 412 
ISRE41, which we also identify in the CXorf21 promoter. Sex differences in the LPS-induced 413 
monocyte response have been previously reported, whereby females have heightened 414 
activation and cytokine release compared with males, although the underlying mechanism has 415 
yet to be delineated42,43.  416 
 417 
rs887369 tags a short 1kb haplotype comprising five perfectly correlated SNPs. The haplotype 418 
is an eQTL for CXorf21, with the risk allele increasing the gene’s expression; we hypothesise 419 
that a self-regulatory mechanism involving modification of H3K36me3 state and chromatin 420 
looping affects RNA polymerase II within the gene promoter (Fig. 8). 421 
 422 
The expression of CXorf21 transcript has previously been shown to be the most accurate 423 
delineator of disease flare from infection in SLE patients18. Interestingly, this previous study 424 
was conducted in largely non-European patients, suggesting the role of CXorf21 is not limited 425 
to individuals of European ancestry. Further supporting our hypothesis that CXorf21 is an IFN-426 
inducible gene, the genes with dysregulated expression at exome-wide significant expression 427 
changes identified in this study are enriched for IFN-inducible genes18.  We observed an age-428 
dependent correlation between CXORF21 expression and disease activity using flow 429 
cytometry in a modest cohort, with CXORF21 protein abundance positively correlating with 430 
SLEDAI in patients <35 years of age. These data warrant further investigation and suggest age-431 
stratified analysis in disease cohorts could be illuminating.   432 
 433 
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The CXORF21 protein has no known function and the primary amino acid sequence gives no 434 
clear clues in this regard.  In an attempt to provide some insight into the function of CXORF21, 435 
we conducted a number of imaging studies to investigate its intracellular location. These 436 
studies showed that CXORF21 is present in both the nucleus and cytoplasm.  Interestingly, we 437 
show that there was some colocalisation of CXORF21 with TLR7 in B cells. This intracellular 438 
toll-like receptor was selected for imaging as it is known to play a role in nucleic acid sensing 439 
in SLE and our analyses revealed some degree of co-expression of TLR7 and CXorf21 at the 440 
RNA level. Intracellular toll-like receptors operate in a complex system involving the 441 
endosomal and lysosomal compartments44. However, the precise points at which CXORF21 442 
and TLR7 may interact within these compartments is not clear on the basis of our data, but 443 
further exploration of this question should reveal more insights into the function of CXORF21 444 
and how it promotes systemic autoimmunity.   445 
 446 
The female-biased sex imbalance of autoimmune diseases is not understood. Our study, which 447 
characterises the SLE association at CXorf21, an IFN-inducible gene which escapes XCI, adds 448 
support to the hypothesis that sex bias in immune function has a genetic basis and provides an 449 
underlying immunological mechanism that underpins the sexual dimorphism in SLE.  450 
  451 
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Methods 452 
European SLE GWAS data 453 
Genotype data from 10,995 individuals of matched European ancestry (4,036 SLE cases, 6,959 454 
controls) genotyped on the Illumina HumanOmni1 BeadChip from the Bentham and Morris et 455 
al15 study were imputed as outlined below. These data had undergone quality control and PCA 456 
as described15.  457 
 458 
Imputation 459 
The European SLE GWAS15, Fairfax et al45,46, and Naranbhai et al47 cohorts were imputed 460 
using UK10K-1000GP3 merged reference panel across the X:30077468-31077846 1Mb 461 
region, plus a 2Mb buffer region (GRCh37 assembly). A full imputation without pre-phasing 462 
was conducted using IMPUTE2 to increase the accuracy of imputed genotype calls48,49. 463 
Imputed genotypes were filtered using an info score (IMPUTE2) threshold of 0.5. The most 464 
likely genotype from IMPUTE2 was taken if its probability was > 0.5. If the probability fell 465 
below this threshold, it was set as missing.  466 
 467 
Allelic and haplotype association fine-mapping  468 
Imputed data from the European SLE GWAS were filtered to include variants with MAF > 469 
0.01 and HWE > 1 x 10-4, and minimum genotype rate > 90%. SNPTEST 2.5.250 was used to 470 
test for additive models of allelic associations across the X:30077468-31077846 1Mb region, 471 
fitting a logistic regression model (including the first four covariates from the original 472 
GWAS15) with equal effect size between males and females50,51. Independent signals were 473 
assessed by including the genotype for the rs887369 SNP as a covariate using the SNPTEST 474 
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algorithm. Association plots were generated using LocusZoom52. Haplotype association 475 
analysis and LD calculations between SNPs were performed using Haploview 4.253 476 
(implementing X-chromosome analysis) using the entire GWAS of 10,995 individuals. 477 
Specifically, haplotype blocks across a 100Kb region anchored on rs887369 were defined by 478 
the confidence internals algorithm54 and haplotype association testing performed by a Chi-479 
Square test using marker thresholds of MAF > 0.01 and HWE > 1 x 10-4, and minimum 480 
genotype rate > 90% (657 SNPs in total).   481 
 482 
We fitted two models for association in SNPTEST. The inactivation model is the default in 483 
SNPTEST’s newmlmethod with male genotypes coded as 0/1 and females coded as 0/0.5/1 484 
and one shared estimated effect (log odds ratio). In the escape model we used SNPTEST with 485 
the stratify_on option which fits separate effects for males and females. In both models, we fit 486 
a different intercept for males and females (using sex as a covariate in the inactivation model) 487 
and so the two models only differ by one parameter (being the differing log odds ratio). A 488 
likelihood ratio test (LRT) on one degree of freedom was performed in R (using the likelihood 489 
values output by SNPTEST), where the escape model was tested against the simpler 490 
inactivation model. A statistically significant result (based on the p-values form the LRT) 491 
would therefore reject the inactivation model.  492 
 493 
Genotype data for ex vivo cell eQTL cohorts 494 
X chromosome SNPs of the Fairfax et al45,46 and Naranbhai et al47 cohorts with an Illumina 495 
GenCall score of <0.7 and called on both X and Y were removed. PLINK v1.955 was used to 496 
remove samples that failed sex check assignments. Following separation of male and females, 497 
SNPs were removed if: HWE < 1x10-4, MAF < 0.01, and SNP missingness > 10%. Individuals 498 
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were removed if >10% of SNPs were missing. Coordinates were converted from hg18 to hg19 499 
using the UCSC liftOver application56.   500 
 501 
Genotype-expression cohorts and cis-eQTL analysis 502 
Gene-level RNA-Seq data from LCLs were downloaded from ArrayExpress (Geuvadis; 503 
EGEUV-1)57 and genotypes (X:30077468-31077846) of these individuals containing SNPs 504 
(MAF > 0.05) were taken from the 1000 Genomes Project Phase III58. Expression data of 505 
purified ex vivo primary immune cells were obtained from Fairfax et al45,46 and Naranbhai et 506 
al47. Details are described in the respective articles. Data include resting B-cells, natural killer 507 
cells, and monocytes45; IFN-γ stimulated monocytes after 24h, LPS stimulated monocytes after 508 
2h, LPS stimulated monocytes after 24h46; and resting neutrophils47. In all instances, cis-eQTL 509 
association analysis (1Mb of rs887369) was performed against expression residuals using the 510 
linear-model of the MatrixeQTL R package59 including the number of PCs described in the 511 
respective articles. 512 
 513 
The TwinsUK RNA-Seq eQTL cohort profiled in LCLs21 was used for cis-eQTL association 514 
analysis in non-skewed females (n=412). Individuals were firstly assessed for skewed X-515 
chromosome inactivation patterns using allele-specific expression of Xist to estimate the 516 
proportion of X inactivation from each parental X chromosome. Individuals were removed if 517 
the allele-specific expression of XIST-linked SNPs was <0.2 or >0.8, these parameters were 518 
chosen on the basis of precedence60–62. cis-eQTL analysis in the twins was performed as above 519 
against exon-count residuals corrected for probabilistic estimation of expression residuals 520 
(PEER) factors and family relatedness63.  521 
 522 
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Differential expression analysis of CXorf21 between males and females using GTEx RNA-Seq 523 
(TMP) data across the 45 cell/tissue types where expression data were available for both sexes 524 
was performed using an unpaired t-test between males and females after grouping by cell/tissue 525 
type. Associations passing the Bonferroni adjusted P-value cut-off of PBF < 0.05 were deemed 526 
significant. 527 
 528 
Cell culture 529 
LCLs were obtained from Coriell Biorepository and cultured in suspension at 5% CO2, 37
°C 530 
in RPMI 1640 medium supplemented with 2mM L-glutamine, 15% foetal bovine serum, 100 531 
units/ml penicillin and 100 µg/ml streptomycin. Cells were seeded every two days to a 532 
concentration of 300,000 viable cells/ml. Individuals used in functional assays were of 533 
European descent (GM12878, HG01702, HG01786, HG01746, HG0111, HG01628, 534 
HG00254, HG12878, HG01501, HG01507, HG01504, HG00269, HG00232).  535 
 536 
qPCR 537 
Total RNA was extracted with the RNeasy Mini Kit (QIAGEN) according to manufacturer’s 538 
instructions. cDNA synthesised with the cDNA Synthesis Kit (Thermo Scientific) and 539 
quantified using the NanoDrop 2000 spectrophotometer. qPCR reactions were performed using 540 
the TaqMan® Universal PCR Master Mix and Universal ProbeLibrary System Technology 541 
(UPL) from Roche.  Primers were purchased from Sigma and reactions performed using the 542 
Applied Biosystems 7500 and subsequent analysis with SDS 2.3. CXorf21 F: 543 
GGATGTTTGACACAGACTTCAAA, R: CCGGATCAGATGAGCAGATT, UPL #65. 544 
ACTB F: AGAGCTACGAGCTGCCTGAC, R: CGTGGATGCCACAGGACT, UPL #9. 545 
Relative abundance and fold change was calculated using the Ct method.  546 
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 547 
Verification of anti-CXORF21 antibody by gene-knockdown 548 
Gene-knockdown of CXorf21 in LCLs (GM12878) was performed by siRNA using the 549 
Nucleofector II Device (Lonza) and Amaxa Cell Line Nucleofector Kit V. Two days before 550 
transfection, cells were seeded to a concentration of 0.5x106 cells/ml. In duplicate, 2x106 cells 551 
were spun at 100g for 10mins and re-suspended in 100l supplemented transfection solution 552 
and 20pmol Silencer Select Pre-Designed & Validated siRNA (Thermo Fisher Scientific) 553 
against CXorf21 (#4392420). The Silencer Select Negative Control No. 1 siRNA (#4390843) 554 
was used as a non-targeting negative control at the same concentration. Cell/siRNA 555 
suspensions were transferred to a Nucleofector cuvette and electroporated using the X-001 556 
programme. Samples were cultured in 1.5ml medium in a 12-well plate and harvested 48 h 557 
post-transfection.  558 
 559 
Immunoblot 560 
Cell lysates were prepared in RIPA buffer (Sigma-Aldrich) and run on a SDS polyacrylamide 561 
gel for electrophoresis. Protein was transferred onto a nitrocellulose membrane and blocked in 562 
5% milk-PBS solution. The rabbit polyclonal anti-CXORF21 antibody (Atlas Antibodies; 563 
HPA001185) was used at a concentration of 1:1,000 and the secondary polyclonal swine anti-564 
rabbit immunoglobulins/HRP (Dako; P0217) at 1:1,000. Membranes were stripped by 565 
Restore™ Western Blot Stripping Buffer (Thermo Fisher) and re-probed with mouse 566 
monoclonal -Actin antibody (Santa Cruz Biotechnology; sc-47778) at 1:4,000 and anti-mouse 567 
IgG HRP conjugate (Promega; W4028) at 1:5,000 or secondary goat anti-mouse IgG HRP 568 
conjugate (Invitrogen; A16078) at 1:10,000. ImageJ was used to calculate the density of the 569 
bands relative to the loading control. Rabbit anti-SQSTM1/p62 (Cell Signalling, 5114) was 570 
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used at a concentration of 1:1,000 and detected with secondary goat anti-rabbit IgG HRP 571 
conjugate (Invitrogen; A16110) at 1:10,000. Raw blots are presented in accompyning Source 572 
Data file.  573 
 574 
Epigenetic fine-mapping 575 
SNPs in X:30077468-31077846 were downloaded from the 1000 Genomes Project Phase III58. 576 
Epigenetic data across all available cell types (n=127) in NarrowPeak format were obtained 577 
from the NIH Roadmap Epigenomics Project22. Peaks were filtered for genome-wide 578 
significance using an FDR threshold of 0.01, and peak widths harmonised to 2kb in length 579 
centred on the peak summit. SNPs were reported as being localised to an epigenetic mark if 580 
they overlapped the 2kb region. The signal value of the epigenetic mark was reported for the 581 
exact coordinate of the SNP using the signal track of the mark in bigWig format visualized 582 
using IGV v2.3.8064.  583 
 584 
NarrowPeak files of ChIP-Seq experiments (H3K4me3, H3K27ac, H3K4me1, H3K36me3, 585 
H3K27me3, H3K9me3, H3K9/14ac, H2A.Zac) were downloaded from the  Blueprint 586 
Epigenome Project ftp site 587 
(http://ftp.ebi.ac.uk/pub/databases/blueprint/data/homo_sapiens/GRCh38/). Only non-588 
diseased cell-types from venous blood were selected for analysis (24 unique cell-types). Using 589 
the GRCh38 genomic positions of the 5 SNPs carried on the associated haplotype, intersection 590 
was performed against the genome-wide binding sites of the selected Blueprint ChIP-Seq 591 
experiments as per the Roadmap Epigenomics project (above). Fold-enrichment of the peaks 592 
that overlapped the associated haplotype were compared by unpaired t-test between males and 593 
female samples for H3K36me3 across different cell-types. 594 
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 595 
Promoter capture Hi-C chromatin interaction data 596 
Chromatin interaction data across a 17 primary immune cell-types was assessed using Capture 597 
Hi-C Plotter (CHiCP; www.chicp.org)25. The study focuses on autoimmune susceptibility loci 598 
from GWAS and ImmunoChip integrating promoter capture Hi-C datasets from three separate 599 
studies65–67. The bait to target coordinates and interaction scores were extracted from CHiCP 600 
manually. Scores were defined by the CHiCAGO algorithm68, where scores ≥ 5 were 601 
considered as significant interactions.       602 
     603 
B-cell isolation and cell stimulation 604 
CD19+ B cells from healthy female subjects (n=49) were isolated by negative selection using 605 
the Dynabeads Untouched Human B Cells Kit (Invitrogen). 1.5-3x106 cells/ml ex vivo B cells 606 
were cultured in RPMI 1640 medium, supplemented with 20% FCS, 2mM L-glutamine and 607 
100 U/mL penicillin/streptomycin.  B cells from 32 of the 49 subjects were incubated with or 608 
without IFN-α 2b (1000 U/ml; PBL Assay Science) at 37°C and 5% CO2. Cells were harvested 609 
after 6 h or 20 h as indicated.  610 
 611 
For immunostaining, human B Cell Isolation Kit II (Miltenyi Biotec). 1x106 cells/ml ex vivo B 612 
cells were cultured in RPMI 1640 medium, supplemented with 10% heat-inactivated FBS, 2 613 
mM L-glutamine and 100 U/mL penicillin/streptomycin. B cells were stimulated with 10 µg/ml 614 
F(ab')2 Fragment Anti-Human IgG+IgM (Jackson ImmunoResearch) and either 0.1 µg/ml 615 
CD40L with 0.1 µg/ml Enhancer (Enzo) or 5 µg/ml resiquimod (Sigma). B cells were 616 
incubated with or without 10 nM bafilomycin A1 (Sigma) for 3 h before harvesting and with 617 
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or without 1000 U/ml IFN-α 2b (PBL Assay Science) at 37°C and 5% CO2. Cells were 618 
harvested after 20 h or 27 h as indicated.  619 
 620 
Ex vivo B cell RNA extraction and array hybridization 621 
RNA was isolated using the RNeasy Mini kit (Qiagen) according to the manufacturer’s 622 
instructions and integrity assessed using the Agilent 2100 Bioanalyzer (Agilent) with the RNA 623 
6000 Pico Kit (RIN < 8 excluded). cDNA was synthesised from 50ng of RNA using the High 624 
Capacity RNA-to-cDNA Kit (Applied Biosystems). Each sample was hybridised to Affymetrix 625 
Human Exon 1.0 ST arrays and expression data were obtained by fluorescence-based detection 626 
using the GeneChip Scanner 3000 7G (Affymetrix). Signal intensities were quantified and 627 
stored as CEL files. 628 
 629 
Quality control of exon array 630 
Quality control was carried out using the probe-set and transcript cluster annotation release 631 
33.1 (GRCh37 build). Probe and probe-set filters were applied to the data as recommended69. 632 
All probe sets targeting RefSeq-annotated RNA transcripts were included. Probes containing 633 
polymorphisms (MAF>0.01) from 1000Genomes were removed. Cross-hybridizing probes 634 
and probe sets containing less than three probes were also excluded. Detection above 635 
background noise (DABG) was calculated for all CEL files and probe-sets were filtered using 636 
Affymetrix Power Tools. Probe sets with DABG P>0.01 in 50% of resting or IFN-α stimulated 637 
samples were removed. Probes and probe-sets that failed QC filters were removed from the 638 
data using Affymetrix Power Tools.  639 
 640 
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Intensity signals were normalized at exon-level and log2-transformed using the robust multi-641 
array average algorithm in the Affymetrix Expression Console software (build 1.2.1.20). Array 642 
hybridization quality was verified using Affymetrix Expression Console according to the 643 
recommendations of the Affymetrix Quality Assessment of Exon and Gene Arrays White 644 
Paper. All arrays showed high hybridization quality and a normal distribution of probe intensity 645 
signals.  646 
PCA was performed using Partek GS version 6.6 (Partek Incorporated) and sample outliers 647 
removed. Duplicate data for one monozygotic twin pair was processed in both batches to be 648 
used as technical replicates and sibling data from the same twin pair within each batch were 649 
used as biological replicates. Correlation between replicates was assessed using a Spearman 650 
correlation test in R. All replicates showed high correlation (r2 > 0.89). A total of 81 samples 651 
from 49 individual twins were included in the analyses.  652 
 653 
Exon array data normalization and analysis 654 
Probe sets were summarized to generate gene-level data by calculating the winsorized mean 655 
(10% and 90%) using Partek GS. Batch effects were accounted for using the sva ComBat 656 
function70. Differential gene expression was calculated using Partek GS with a mixed-model 657 
analysis of variance (ANOVA) as follows: Y = µ + treatment + individual ID + twin ID + PC1 658 
+ PC3 + error. The fitted ANOVA model regressed expression levels at each gene (Y) on fixed-659 
effect terms (treatment, explained by PC2) and on random-effect terms denoting individual ID, 660 
family structure and zygosity (twin ID) and PCs explaining most of the data variability (PC1 661 
and PC3).  662 
 663 
31 
 
SLE Patients and Healthy Controls 664 
Female patients meeting the American College of Rheumatology (ACR) criteria for the 665 
definition of SLE active disease71 were recruited from Louise Coote Lupus unit, Guy’s Hospital 666 
(n=19), following informed consent and with ethical approval (Research Ethics Committee; 667 
REC 12/LO/1273 and REC 07/H0718/49) and SLE Disease Activity Index (SLEDAI) scores 668 
were calculated72. The investigator was blinded to SLEDAI scores during measurment of 669 
CXORF21 protein abundance. Healthy female controls were recruited from the TwinsUK 670 
Bioresource. The TwinsUK study is approved by the research ethics committee at St Thomas 671 
Hospital, London. Volunteers gave informed consent and signed an approved consent form 672 
prior to participation. Volunteers were supplied with an appropriate detailed information sheet 673 
regarding the research project and procedure by post prior to attendance. 674 
 675 
PBMC isolation 676 
20ml of whole blood in EDTA anti-coagulant was taken from female volunteers (SLE or 677 
healthy controls). Peripheral blood mononuclear cells (PBMCs) were separated from whole 678 
blood using Histopaque-1077 Hybri-Max (Sigma-Aldrich) density centrifugation and plated at 679 
2x106 cells/ml in RPMI 1640-medium (Gibco) supplemented with 10% foetal calf serum 680 
(FCS), 2mM L-glutamine and 100 U/mL penicillin/streptomycin (all from Invitrogen).  681 
 682 
Flow Cytometry  683 
PBMCs were first incubated with Human TrueStain FcX (5ul; BioLegend) to block Fc 684 
receptors, before cell-surface staining with 1l anti-human CD14 PerCP-Cy5.5 (eBioscience; 685 
45-0149-42) and 1l anti-human CD19 PE (eBioscience;12-0198-42) for 20min on ice. Cells 686 
were fixed with 200ul 1X stabilising fixative (BD biosciences) and then permeabilized in 0.1% 687 
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Triton X-100 (Sigma-Aldrich). Fc blocker was again added before intracellular staining of 688 
0.1μg rabbit polyclonal anti-human CXORF21 (Atlas antibodies; HPA001185) or 0.1μg rabbit 689 
monoclonal IgG isotype control (Abcam; ab172730), as appropriate, for 60min on ice. 690 
Following washing, cells were incubated with secondary goat anti-rabbit-Alexa Fluor 488 691 
(Abcam; ab150077) antibody at 1:2000. Cells were washed and resuspended in 250μl PBS for 692 
analysis on BD FACSCanto™ II cytometer (BD Biosciences) using BD FACSDiva software 693 
(version 8.0.1; BD Biosciences). Compensation was performed using compensation beads (BD 694 
Biosciences), and cytometer settings were standardised using Cytometer Setup and Tracking 695 
Beads (BD Biosciences). Following data acquisition, FlowJo v.10.1 software was used to 696 
calculate the Median fluorescent intensity (MFI). An unpaired Student’s t-test was used for 697 
case-control analyses. Logistic regression models were fitted for CXORF21 abundance as a 698 
function of SLEDAI, and as a function of SLEDAI stratified by age (under/over 35 years of 699 
age) with an interaction term. The models were compared using a likelihood ratio test (LRT; 700 
d.f. = 5) and BIC using R. Multiple testing was corrected using Bonferroni correction. 701 
Preliminary results showed no expression of CXORF21 on cell surface.  702 
 703 
ImageStream Analysis 704 
Multispectral imaging flow cytometry (MIFC) was performed on an ImageStreamX (Amnis) 705 
instrument. Golgi colocalisation: 2 x 106 cells were fixed with 200ul 1X stabilising fixative 706 
(BD biosciences) and then permeabilized in 0.1% Triton X-100 (Sigma-Aldrich). Fc blocker 707 
was added before intracellular staining with 0.1μg rabbit polyclonal anti-CXORF21 antibody 708 
(Atlas antibodies; HPA001185) and  secondary goat anti-rabbit Alexa Fluor 488 (Abcam; 709 
ab150077) at 1:2000. Cells were then incubated for 60min on ice with 0.1μg anti-GM130-710 
Alexa Fluor 647 (Abcam; ab195303).  Lysosomal and nuclear colocalisation: 2 x 106 cells were 711 
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incubated at 37°C for 15mins in 1X Assay Buffer and 0.1µl Lyso-ID Red Detection Reagent 712 
and 0.1µl Hoechst 33342 Nuclear Stain (Lyso-ID Red Detection Kit; Enzo; anti-ENZ-51005-713 
0100). Cells were then fixed with 200ul 1X stabilising fixative (BD biosciences) and 714 
permeabilized in 0.1% Triton X-100 (Sigma-Aldrich). Fc blocker was added before 715 
intracellular staining with 0.1μg rabbit polyclonal anti-CXORF21 antibody (Atlas antibodies; 716 
HPA001185) and  secondary goat anti-rabbit Alexa Fluor 488 (Abcam; ab150077) at 1:2000. 717 
Cells were resuspended in 60µl PBS. Up to 100,000 images were acquired per sample. Cells 718 
were gated on aspect ratio to include only singlets, and the gradient root-mean-square feature 719 
to include focused cells. Using the co-localisation mask on the IDEAS software (Amnis), we 720 
calculated the overlap of CXORF21 and organelle markers for cellular localisation. 721 
 722 
Immunostaining of autophagic LC3-II and CXORF21 723 
1x106 cells/ml LCL were starved in EBSS with or without 10 nM or 100 nM bafilomycin A1 724 
(Sigma) for 3 h at 37°C and 5% CO2 before harvesting, when starvation was required. For LC3 725 
staining, the cells were selectively permeabilized with 0.05% saponin prior to fixation. Cells 726 
were fixed in 4% formaldehyde for 20 min at room temperature, then permeabilized with 0.1% 727 
Triton X-100 and 2% goat serum (both Sigma-Aldrich) in PBS for 30 min on ice. After 728 
overnight incubation in 5% goat serum, cells were Fc receptor blocked (Human TruStain FcX, 729 
Biolegend) and incubated with 2 µg/ml rabbit anti-human CXORF21 (Atlas antibodies; 730 
HPA001185) and either 2 µg/ml mouse anti-human TLR7 (Novus Biologicals, NBP2-27332) 731 
or 40 µg/ml mouse anti-human LC3 (MBL, M152-3) in 5% goat serum for 1 h on ice. 732 
Following washing, cells were stained with goat anti-rabbit Alexa Fluor 488 (Abcam; 733 
ab150077) and goat anti-mouse Alexa Fluor 594 (Abcam; ab150116), both at 1:2000, in 5% 734 
goat serum for 30 min on ice. Cells were washed and mounted in ProLong™ Gold Antifade 735 
Mountant containing DAPI (Invitrogen). 736 
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 737 
Imaging and Analysis 738 
Imaging was performed at the Nikon Imaging Centre at King’s College London. Z stacks were 739 
acquired at 0.12 µm step size on an Eclipse Ti-2 Inverted microscope with Vt-iSIM scan head 740 
and Hamamatsu Flash4.0 sCMOS camera using a 100x oil immersion objective. Laser settings, 741 
image capture and Richardson-Lucy deconvolution were managed in NIS-Elements. Images 742 
were further processed and Pearson’s correlation coefficient and Mander’s colocalisation 743 
coefficient were calculated using the Colocalization Studio plugin73 in Icy software. Maximum 744 
intensity projections are shown for better visualisation. A one-way ANOVA with Tukey 745 
multiple comparison correction was performed to test for statistical significance in GraphPad 746 
Prism v7.04. 747 
 748 
Data availability 749 
Summary statistics on 10,995 individuals of matched European ancestry (4,036 SLE cases, 750 
6,959 controls) genotyped on the Illumina HumanOmni1 BeadChip are available at 751 
http://insidegen.com/insidegen-LUPUS-data.html. TwinsUK RNASeq data are deposited in 752 
European Genome-Phenome Archive (EGAS00001000805). The UK10K (REL-2012-06-02) 753 
plus 1000 Genomes Project Phase3 data (release 20131101.v5) merged reference panel 754 
(UK10K-1000GP3) was accessed through the European Genome-phenome Archive 755 
(EGAD00001000776). All other data are contained within the article and its supplementary 756 
information or upon reasonable request from the corresponding author. The source data 757 
underlying Figures 2d, 6e-f, 7e-g, and Supplementary Figures 2b, 3, 6b, 12 and 13  are provided 758 
as a Source Data file. 759 
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Figure Legends 910 
Figure 1: Genetic refinement of the Xp21.2 (rs887369) SLE suseptability locus.  911 
(A) Association plot of the 1Mb region (X:30,077,846-31,077,845) of SLE-associated region 912 
Xp21.2 following genotype imputation to the level of UK10K-1000G Phase III and association 913 
testing as described (n = 10,995 individuals of European ancestry). rs887369 is shown as the 914 
most significantly associated lead SNP. Genetic association plots were generated using 915 
LocusZoom. (B) Association plot of the 1Mb region following conditional analysis on lead 916 
SNP rs887369. (C) Haplotype construction and visualisation of the Xp21.2 SLE susceptibility 917 
locus conducted in Haploview 4.2. The top panel shows the structure of the three blocks and 918 
haplotypes surrounding the lead SNP rs887369 (highlighted in red, block B, SNP #15). Blocks 919 
are separated by regions of high recombination as specified by D and r2. The frequency of 920 
each haplotype is denoted. The middle panel presents the colour-coded haplotypes and 921 
individual SNPs by their genomic coordinates around CXorf21. The bottom panel shows the 922 
LD structure and pair-wise correlation (r2) of SNPs, and length of each block. (D) Right table: 923 
case-control association analysis of each haplotype using Haploview 4.2.  924 
 925 
Figure 2: eQTL association analysis of SLE associated risk SNP rs887369 in immune cell 926 
types.  927 
(A) Cis-eQTL analysis of rs887369 using male samples of the Geuvadis RNA-Seq expression 928 
cohort profiled in LCLs. The MAGEB family of genes and NR0B1 were not expressed in LCLs 929 
(RPKM < 1). Allele [C] of rs887369 tags the risk haplotype. The number underneath each box-930 
plot represents the mean of the group and the number underneath the x-axis refers to the number 931 
of inviduals in each group. (B) Cis-eQTL analysis performed for all SNPs in cis (+/-1Mb) to 932 
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rs887369 against CXorf21 expression using the males of the Geuvadis cohort. The coordinate 933 
of each SNP is plotted on the x-axis and the –log10(P) value of association on the y-axis; 934 
rs887369 is highlighted as the best eQTL. (C) cis-eQTL analysis of rs887369 against CXorf21 935 
expression in LCLs from the TwinsUK cohort using only females who exhibit non-skewed 936 
patterns of X-chromosome inactivation (see methods). (D) Relative protein abundance of 937 
CXORF21 in LCLs from females stratified on genotype at the rs887369 SNP. Relative 938 
abundance normalized against beta-actin loading control. Source data are provided in the 939 
Source Data file (E) Cis-eQTL analysis of rs887369 using the microarray data from the Fairfax 940 
et al45,46 and Naranbhai et al47 cohorts in primary ex vivo immune cell types (see Methods). 941 
The remaining cis-genes did not pass quality control. Box-plots show minimum (Q1-1.5*IQR), 942 
25th percentile (Q1), Median, 75th percentile (Q3), and maximum Q3+1.5*IQR.  943 
 944 
Figure 3: Functional priorization of causal variants at the Xp21.2 SLE suceptibility locus. 945 
The five SNPs carried on the risk haplotype attributed to SLE susceptibility and modulation of 946 
CXorf21 gene expression were epigenetically fine-mapped using chromatin data from the 947 
Roadmap Epigenomes Project (twelve different marks across 127 cell/tissue types). (A) The 948 
five SNPs localised to significant H3K36me3 modification sites in five immune cell types. The 949 
heatmap shows the fold-enrichment of H3K36me3 between cell-types across SNP positions. 950 
(B) Signal tracks of H3K36me3 in primary monocytes (blue) and primary neutrophils (red) 951 
from peripheral blood across the CXorf21 susceptibility locus. Only rs887369 localises to the 952 
binding site summit of H3K36me3 in these two cell types. (C) Promoter-capture Hi-C 953 
interaction of the rs887369 target locus (chrX :30576528-30582605) with four bait loci across 954 
17 primary immune cell types from healthy human donors (Note that the majority of the 955 
samples are pooled from multiple donors making it impossible to deconvoloute the sex and 956 
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genotypes of the individuals). Interaction #1 is the interaction between the association target 957 
region (at the 3 end of CXorf21) and the CXorf21 promoter region. (D) Heatmap of strength 958 
of interaction (CHiCAGO score) of the four interactions across immune cell types. (E) 959 
Correlation of interaction score for interaction #1 (3 of CXorf21 and CXorf21 promoter) with 960 
Roadmap Epigenomes Project chromatin marks found at the CXorf21 promoter across different 961 
immune cell types. Higher interactions are correlated with greater enrichment of active 962 
chromatin marks suggesting the interaction to regulate gene expression is cell-type specific.  963 
 964 
Figure 4: Expression of CXorf21 in primary ex vivo cells stratified on sex and cellular 965 
activation.  966 
CXorf21 expression data in resting and stimulated monocytes from healthy individuals of 967 
European ancestry derived from the Fairfax et al studies (see Methods; n = 322 biologically 968 
independent samples). Samples were separated based on sex and activiation condition: 969 
following stimulation with interferon gamma (IFN-) or with lipopolysaccharide (LPS) and 970 
harvested after 24 hours. For each group, the mean is reported in the corners and the effect size 971 
(Cohen's d) is reported along the corresponding three-dimenstional regression plane. Plots were 972 
constructed using plot3D for R. Source data are provided as a Source Data file.   973 
 974 
Figure 5: CXorf21 as an interferon response gene 975 
(A) Differential gene expression of X chromosome genes in response to IFN- stimulation 976 
(harvested after 6 h) in primary ex vivo B cells from healthy females of European ancestry (in-977 
house data). Genes highlighted in red are significantly differentially expressed (q < 0.01; 978 
absolute fold-change > 2). (B) Epigenetic landscape of CXorf21 using ENCODE transcription 979 
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factor binding data in LCLs (GM12878 cell line). All five transcription factors have genome-980 
wide significant binding sites at the CXorf21 promoter. Heat colour is a function of signal 981 
strength (fold-change over input).  982 
 983 
Figure 6: Super resolution microscopy of CXORF21 and TLR7 984 
Structured Illumination Microscopy data showing colocalisation of TLR7 and CXORF21 in ex 985 
vivo B cells.  Representative results on individual cells are shown in panels A through D with 986 
TLR7 staining in the first column, CXORF21 in the second column, DAPI nuclear staining in 987 
column three, and in the fourth column all three stains are merged: TLR7 (magenta), CXORF21 988 
(green) and DAPI (blue).  The B cells are under different conditions in the panels: (A) resting, 989 
(B) resting and IFN-α treated (1,000U/ml), (C) Ig/CD40 stimulated, and (D) Ig/CD40 990 
stimulated and IFN-α treated ex vivo B cells at 20 hours. Maximum intensity projections are 991 
shown. Scale bar in white on bottom left hand corner is 2 µm. (E) Plot showing the correlation 992 
co-efficients () between TLR7 and CXORF21 staining of multiple B cells quantified using 993 
the results from Z-stack images from individual cells (represented as open circles).  From left 994 
to right: unstimulated cells (n=84), cells stimulated with IFN-α (n=60), B cells stimulated with 995 
Ig/CD40 (n=32), B cells stimulated with Ig/CD40 and IFN-α (n=22).  The horizontal bar 996 
represents the mean correlation co-efficient () and the bars above and below this denote the 997 
standard deviation of the distribution. (F) Mander’s colocalisation coefficient (M2) between 998 
TLR7 and CXORF21 are shown from Z-stack images from single B cells (represented as open 999 
circles).  From left to right: unstimulated cells (n=84), cells stimulated with IFN-α (n=60), B 1000 
cells stimulated with Ig/CD40 (n=32), B cells stimulated with Ig/CD40 and IFN-α (n=22).  The 1001 
horizontal bar represents the mean colocalisation co-efficient (M2) and the bars above and 1002 
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below this denote the standard deviation of the distribution. Source data are provided as a 1003 
Source Data file.  1004 
 1005 
Figure 7: CXORF21 and the autophagosome 1006 
Structured Illumination Microscopy data showing colocalisation of LC3 and CXORF21 in ex 1007 
vivo B cells.   Representative results on individual cells are shown in panels A through D with 1008 
LC3 staining in the first column, CXORF21 in the second column, DAPI nuclear staining in 1009 
the third column, and in the fourth column all three stains are merged: LC3 (magenta), 1010 
CXORF21 (green) and DAPI (blue).  In panel (A) B cells were Ig/CD40 stimulated, (B) 1011 
Ig/CD40 stimulated and bafilomycin-treated, (C) Ig and TLR7/8 stimulated, and (D) Ig and 1012 
TLR7/8 stimulated and bafilomycin-treated after 27 hours. Maximum intensity projections are 1013 
shown. Scale bar in white on bottom left hand corner is 2 µm. (E) Plot showing the correlation 1014 
co-efficients () between LC3 and CXORF21 staining quantified using the results from Z-stack 1015 
images, individual B cells are represented as open circles.  From left to right: Ig/CD40 1016 
stimulated cells (n=17), Ig/CD40 stimulated cells in the presence of 10nM bafilomycin (n=22), 1017 
B cells stimulated with Ig and resiquimod (n=21), B cells stimulated with Ig and resiquimod 1018 
in the presence of 10nM bafilomycin (n=32).  The horizontal bar represents the mean 1019 
correlation co-efficient () and the bars above and below this horizontal bar denote the 1020 
standard deviation of the distribution. (F) Mander’s colocalisation coefficient (M2) between 1021 
LC3 and CXORF21 are shown from Z-stack images, individual B cells are represented as open 1022 
circles.  From left to right: Ig/CD40 stimulated cells (n=17), Ig/CD40 stimulated cells in the 1023 
presence of 10nM bafilomycin (n=23), B cells stimulated with Ig and resiquimod (n=21), B 1024 
cells stimulated with Ig and resiquimod in the presence of 10nM bafilomycin (n=32).  The 1025 
horizontal bar represents the mean colocalisation co-efficient (M2) and the bars above and 1026 
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below this denote the standard deviation of the distribution. (G) Western blot analysis of 1027 
protein extract from starved LCL, in the left-hand blot CXORF21 is quantified in the absence 1028 
of bafilomycin and after 10nM and 100nM treatment.  The amount of CXORF21 was quantified 1029 
by densitometry and the relative abundance shown against a beta actin control, using the 1030 
unstimulated conditions as a reference point.  In the right-hand blot sequestosome 1 (p62) is 1031 
quantified in the absence of bafilomycin and after 10nM and 100nM treatment.  The amount of 1032 
Sequestosome-1 was quantified by densitometry and the relative abundance shown against a 1033 
beta actin control, using the unstimulated conditions as a reference point. Source data are 1034 
provided as a Source Data file.  1035 
 1036 
Figure 8: Summary of factors influencing expression of CXorf21 at RNA and protein 1037 
level. 1038 
We summarise five factors increasing the cellular abundance of CXorf21 either at RNA level 1039 
or protein level across a range of immune cell types. These are: (1) genetic variation at SLE 1040 
susceptibility haplotype - tagged by SNP rs887369 - where the risk haplotype [C] may drive 1041 
up-regulation by modulation of chromatin interaction and/or modification of H3K36me3 state; 1042 
(2) female sex, in which escape from X-inactivation results in an increased amount of transcript 1043 
and protein in females; (3) X chromosome aneuploidy; (4) type I and type II interferons, and 1044 
LPS, increase the expression of CXorf21 in ex vivo B cells and monocytes; (5) ancestry – 1045 
potentially linked to the minor allele frequency of rs887369 – in which higher levels of CXorf21 1046 
transcript is observed in LCLs derived from donors with European ancestry. We hypothesise 1047 
that elevation of CXORF21 is a risk factor for developing SLE and that this is may be mediated 1048 
through it’s role in the endosomal pathway. Figure generated by C.A.O.   1049 
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